Sodium–glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction – lessons from clinical trials. Letter regarding the article ‘Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF’